Join this Featured Workgroup!
Elite Investors

This group is for elite investors and traders that are dedicated to participating in an active community that wants to learn from each other, share their research, and work together to do deep analysis of securities. The moderator of this group taught securities analysis at UCLA and is dedicated to helping other investors improve their abilities.

In this private group, membership is restricted and regular contributions are required. Any member not contributing on a regular basis will be removed to make room for a new member.

In your application messsage, please share your background and what you can contribute to the group.



Company Overview and News

0
Page Industries Limited - Shareholders meeting

2018-07-18 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
PGDQY PAGEIND 532827

0
Page Industries Limited - Updates

2018-07-18 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
PGDQY PAGEIND 532827

0
TCNS Clothing: Tailored for the risk-taker

2018-07-18 premium.thehindubusinessline
Increasing number of working women, higher disposable incomes and growing footprint of organised retail across the country are among factors driving the demand for branded women’s apparel in India. TCNS Clothing is a play on this trend.
PGDQY PAGEIND 532827 532732 KKCL

0
Will IPO of TCNS activate listed players?

2018-07-17 thehindubusinessline
Shares such as Arvind, Kewal Kiran Clothing, Future Lifestyle, Aditya Birla Fashion and Retail, Page Industries and Trent will remain in focus as TCNS Clothing Company's public issue opens for subscription on Wednesday in a price band of ₹714-716 a share. Strong response from investors to the IPO of TCNS Clothing - a women’s branded apparel company - may boost sentiment for the listed players too, in the secondary market.
PGDQY PAGEIND 532827 532732 KKCL

8
Sensex ends mildly higher amid volatile moves, Nifty above 10,850-mark; pharma gains big

2018-06-13 moneycontrol
Some selling pressure gripped the market in the last hour of trade as investors may have turned cautious ahead of US Federal Reserve’s policy meet decision later in the day.
PGDQY PAGEIND RCOM RUCHISOYA 532827 IDEA ICLQY 500368 532712 500493 532822 BHARATFORG

0
Page Industries hits record high

2018-06-13 thehindubusinessline
Shares of Page Industries Ltd jumped as much as 6.5 per cent to their all-time high of Rs 26,320. The stock posted its biggest intraday percentage gain since May 25.
PGDQY PAGEIND 532827

0
Page Industries Limited - Updates

2018-06-12 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
PGDQY PAGEIND 532827

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...